BHST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioHarvest Sciences Inc (BHST) is not an optimal buy for a beginner investor with a long-term focus at this moment. While the company shows promising revenue growth and a positive outlook from analysts, the lack of profitability, declining net income, and bearish technical indicators suggest waiting for a better entry point.
The MACD is positive and expanding, indicating potential upward momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a lack of strong upward trend. The stock closed at $4.75, above the pivot point of $4.65 but below the first resistance level of $4.94.
Analyst Sean McGowan from Roth Capital initiated coverage with a Buy rating and a $10 price target, citing rapid growth, an expanding footprint, and emerging profitability. Revenue increased by 38.66% YoY in Q3 2025, and gross margin improved to 61.43%.
The company remains unprofitable, and insiders and hedge funds have shown no significant trading activity. Technical indicators are mixed, with bearish moving averages.
In Q3 2025, revenue increased to $9,067,000 (up 38.66% YoY), but net income dropped to -$2,513,000 (down 6.55% YoY). EPS fell to -0.14 (down 12.50% YoY), while gross margin improved to 61.43% (up 8.15% YoY).
Roth Capital analyst Sean McGowan initiated coverage with a Buy rating and a $10 price target, citing significant revenue growth potential and emerging profitability starting in 2027.
